BAUM CHARLES M 4

What Happened

• Charles M. Baum, a director of PMV Pharmaceuticals, was granted 42,000 derivative equity awards (reported as an "A" — award/grant) on June 4, 2026. The filing shows an acquisition price of $0.00 (total reported value $0).
• The award is a derivative grant (footnote describes it as an option) and is subject to vesting conditions.

Key Details

• Transaction date: 2026-06-04; Form 4 filed 2026-06-05 (appears timely).
• Type: Award/Grant of derivative securities (Form 4 code A).
• Amount: 42,000 shares/options; price $0.00; reported value $0.
• Vesting: Footnote F1 — vests on the earlier of (i) June 4, 2027 or (ii) the issuer’s next annual meeting of stockholders.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• No indication of a 10b5-1 plan, cashless exercise, or tax-withholding sale in this filing.

Context

• These are compensation awards that vest in the future (not an immediate market purchase). Until vested/exercised and sold, they do not increase liquid insider holdings. Grants are common for directors and are compensation-related rather than a direct buy/sell indicating market sentiment. Monitor future filings for vesting, exercises, or any subsequent sales.